arrow
A

Alexander M. Menzies

Melanoma Institute Australia
H指数:85
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of Immediate Therapeutic Lymph Node Dissection Instead of Index Lymph Node After Neoadjuvant Checkpoint Inhibitors: Lessons Learned from the PRADO Trial

新辅助免疫检查点抑制剂治疗后立即进行非原发淋巴结清扫的预测因素:PRADO试验的经验教训

2026-10-240
PRE
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

在临床上可检测的III期黑色素瘤中,新辅助免疫治疗后,通过减少肿瘤床检查,病理反应计算评估仍然准确。

2025-11-010
PRE
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)

AXIOM研究:一项关于1-5个颅内外黑色素瘤寡转移患者中,同步立体定向体部放射治疗联合免疫治疗与单纯免疫治疗对比的随机II期试验研究方案

2025-10-230
OAAI
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours

疫苗诱导的免疫在胶质瘤患者中维持,与其他实体瘤相比。

2025-10-150
OA
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

III期黑色素瘤辅助治疗中的动态复发风险预测工具

2025-09-120
PRE
Targeted Therapy for Rare BRAF-Mutated Melanoma: Updated Multicenter Analysis and Launch of a Publicly Accessible Online Outcome Database

靶向治疗罕见BRAF突变黑色素瘤:更新后的多中心分析及公共可访问在线结局数据库的建立

2025-08-090
PRE
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis

POLARIS研究的简明语言摘要:一项针对BRAF V600突变黑色素瘤脑转移患者,评估encorafenib联合binimetinib不同剂量的研究

2025-05-260
OA
Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor-and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease

68Ga-NeoB PET/CT在雌激素受体和孕激素受体阳性乳腺癌患者转移性疾病分期或再分期中的诊断潜力

2025-03-270
PRE
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Fdg-pet与黑色素瘤新辅助免疫治疗的病理反应和生存率的关系

2025-03-250
OA
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance (vol 40, pg 88, 2022)

多组学分析:检查点抑制剂治疗的黑色素瘤:识别应答和耐药的预测因子,以及生物学不一致性的标志物(卷40,页88,2022)

2025-02-010
PRE
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

晚期 Merkel Cell Carcinoma 患者接受抗 PD-(L)1 疗法后进展性疾病的治疗结果与管理

2025-02-010
PRE
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial

新辅助抗PD-1单药或联合抗TIGIT或溶瘤病毒在可切除的III B-D期黑色素瘤中的应用:一项I/II期临床试验

2025-01-072
OA
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
2025-01-010
PRE
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

头颈部皮肤黑色素瘤和其他部位黑色素瘤的临床病理特征和治疗结果的比较: 全身治疗的意义

2025-01-011
OAAI